Previous 10 |
SAN DIEGO and VANCOUVER, British Columbia , March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the trea...
SAN DIEGO and VANCOUVER, British Columbia , Dec. 17, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatmen...
NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Shares of Opiant saw big gains after Wall Street learned that Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opia...
SAN DIEGO and VANCOUVER, British Columbia , Aug. 29, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for th...
Gainers: OPNT +50% . IGC +40% . GKOS +36% . EVFM +26% . IPAS +27% . SPHS +27% . AFMD +25% . JMU +19% . YRD +17% . ZYNE +17% . More news on: Opiant Pharmaceuticals, Inc., India Globalization Capital, Inc, Glaukos, Stocks on the move, , Read more ...
OPNT +79% on EBS takeout of Adapt Pharma. More news on: Opiant Pharmaceuticals, Inc., Glaukos, India Globalization Capital, Inc, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO and VANCOUVER, British Columbia , May 18, 2020 /PRNewswire/ -- Sophiris Bio Inc. (OTCQB: SPHS) (the "Company" or "Sophiris"), today announced that its board of directors has formally approved an immediate shutdown of the operations of the Company. The Compa...
SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tre...
SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseas...